Gastro-resistant mercaptamine, marketed as Procysbi, has been accepted for use within NHS Scotland for the treatment of ...

With a favourable safety profile and consistent activity across tumour types, agenT-797 is now poised to enter phase 2 trials. MiNK believes the therapy could redefine treatment for patients with ...

The Christie NHS Foundation Trust has completed a four-month digital transformation project using Netcall’s Liberty Spark to ...

Santhera Pharmaceuticals has announced positive topline results from a long-term analysis of AGAMREE (vamorolone) in patients ...

MND isn’t incurable, it’s underfunded ...

Heidelberg Pharma has reported encouraging progress in its phase 2/2a trial of HDP-101 (INN: pamlectabart tismanitin), its ...

Women’s health issues have historically been under-researched, marginalised and underserved. This systemic neglect has led to ...

Rebuilding the clinical trials landscape in the UK ...

Alys Pharmaceuticals has announced the dosing of the first subject in its phase 1/1b trial of ALY-301, a first-in-class mast ...

Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial evaluating ...

What is, exactly, going on with the NHS at the moment? You could be forgiven for thinking the fireworks of this summer’s ...

Theolytics has named Matilde Saggese as its new Chief Medical Officer, as the Oxford-based biotech company accelerates ...